Metabolicdiseaseisadisordercomprisinginsulinresistance,glucoseintolerance,dyslipidemia,hypertensionandobesity,inparticularabdominalobesity.Metabolicdiseaseisoneofthemostimportantchallengesfacingpublichealthandbiomedicalresearch,theprevalenceofwhichisincreasingworldwideasaresultofchangesindietandlifestyle.Peoplewithmetabolicdiseasehaveahigherriskofdevelopingdiabetesandcardiovasculardisease.
Invivomodelsareimportantresourcesforstudyingthephysiologicalmechanismsofmetabolicdisordersaswellaspreclinicaltranslation,whichmayincludetheassessmentofnewtreatments.Inthestudyofmetabolicdisease,invivomodelshaveuniqueadvantagesoverinvitromodels,whicharelimitedtoinvestigationofisolatedsystems.
CreativeBioarrayprovidesanumberofrodentmodelsintheareasofdiabetes,obesity,dyslipidemiaandNASH.Thesemodelswillhelptodeterminethepathophysiologicalbasisofmetabolicdisordersandhowthemetabolicdisordersincreasetheriskofotherdiseases.
AtCreativeBioarray,weconductmetabolicresearchincludingthefollowingassessments:
CreativeBioarrayhastheexpertiseandexperiencetoassistyouinassessingthetherapeuticpotentialofyourcompoundsforobesity,diabetesandassociateddisorders.WeprovidearangeofanimalmodeltestingsystemstopromoteyourdrugcandidatesfromdiscoverytoIND.Disease-associatedbiomarkerscanalsobeinvestigatedatCreativeBioarraybyusingchemistrypanels,completebloodcounts,ELISA's and lipid panels. In addition, our experts have the experience and infrastructure to study the interactions between microbiome and metabolic diseases, adding a novel and important aspect to your drug development research. Contact us today to discuss your objectives and how we can reach them.